<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0864-0300</journal-id>
<journal-title><![CDATA[Revista Cubana de Investigaciones Biomédicas]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cubana Invest Bioméd]]></abbrev-journal-title>
<issn>0864-0300</issn>
<publisher>
<publisher-name><![CDATA[ECIMED]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0864-03002021000400028</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Costo beneficio de acetaminofén en tableta en establecimientos farmacéuticos de Lima]]></article-title>
<article-title xml:lang="en"><![CDATA[Cost benefit of acetaminophen in tablet in pharmaceutical establishments of Lima]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Morales Ramos]]></surname>
<given-names><![CDATA[Jorge Guillermo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Esteves Pairazamán]]></surname>
<given-names><![CDATA[Ambrocio Teodoro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Soledad Mocarro Willis]]></surname>
<given-names><![CDATA[María Ema]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Quispe Brañez]]></surname>
<given-names><![CDATA[Jennifer Rosmery]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Melgarejo Angeles]]></surname>
<given-names><![CDATA[Wilder Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Señor de Sipán S.A.C  ]]></institution>
<addr-line><![CDATA[ Chiclayo]]></addr-line>
<country>Peru</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Privada Norbert Wiener  ]]></institution>
<addr-line><![CDATA[ Lima]]></addr-line>
<country>Peru</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad Nacional San Luis Gonzaga  ]]></institution>
<addr-line><![CDATA[ Ica]]></addr-line>
<country>Peru</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2021</year>
</pub-date>
<volume>40</volume>
<numero>3</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0864-03002021000400028&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0864-03002021000400028&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0864-03002021000400028&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  La economía de los medicamentos se puede considerar como el estudio y cálculo económico detallados del medicamento, que ayuda a satisfacer las necesidades del paciente según costo, beneficio y eficacia de dicho medicamento.  Objetivo:  El objetivo de la investigación fue evaluar si la valoración económica de la tableta de acetaminofén 500 mg. permitirá conocer el beneficio en el costo del fármaco en los establecimientos farmacéuticos de Lima.  Métodos:  La investigación presenta un diseño no experimental, transversal, descriptivo y analítico. Población: 25 trabajadores de la DIGEMID con conocimientos de farmacoeconomía; muestra: 100% de la población. Para la evaluación se utilizó un cuestionario de escala Likert, basado en las dos variables cuantitativas: Valoración económica y Coste-beneficio. El tratamiento estadístico se realizó con el programa SPSS v.25. Traducción realizada con la versión gratuita del traductor www.DeepL.com/Translator  Resultados:  De un total de 44 presentaciones de tabletas de acetaminofén vendidas en 41 distritos de Lima, se obtuvieron siete presentaciones que ofrecen el producto a un precio elevado, siendo estas no beneficiosas en el 15,9 % y se encontraron 37 establecimientos que ofrecen el medicamento a un precio medio beneficioso (84,1 %).  Conclusiones:  La farmacoeconomía aplicada al medicamento acetaminofén presentación tableta 500 mg permitió conocer que dicho producto tiene un costo de bajo a moderado, por lo que es asequible a la población de bajos recursos. Asimismo, la evaluación económica efectuada permitirá la toma de decisiones del consumidor al momento de la compra.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  The economics of medicines can be considered as the detailed economic study and calculation of the treatment, which helps to satisfy the needs of the patient according to the cost, benefit, and efficacy of said medicine.  Objective:  The objective of the research was to evaluate if the economic valuation of the acetaminophen 500 mg. tablet will allow to know the benefit in the cost of the drug in pharmaceutical establishments in Lima.  Methods:  The research presents a non-experimental, cross-sectional, descriptive, and analytical design. Population: 25 DIGEMID workers with knowledge of pharmacoeconomics; sample: 100% of the population. A Likert scale questionnaire was used for the evaluation, based on the two quantitative variables: Economic valuation and Cost-benefit. Statistical processing was carried out using the SPSS v.25 program.  Results:  From a total of 44 presentations of acetaminophen tablets sold in 41 districts of Lima, seven presentations have been obtained that offer the product at a high price, these being not beneficial and reaching 15.9%, 37 establishments were found They offer the drug at a helpful average price reaching 84.1%.  Conclusions:  The pharmacoeconomics applied to the drug acetaminophen 500 mg tablet presentation allowed us to know that this product has a low to moderate cost, making it affordable to the low-income population. Likewise, the economic evaluation carried out will allow decision-making at the time of purchase, which will enable the people to identify the price.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[acetaminofén]]></kwd>
<kwd lng="es"><![CDATA[farmacoeconomía]]></kwd>
<kwd lng="es"><![CDATA[costo-beneficio]]></kwd>
<kwd lng="es"><![CDATA[evaluación]]></kwd>
<kwd lng="en"><![CDATA[acetaminophen]]></kwd>
<kwd lng="en"><![CDATA[pharmacoeconomics]]></kwd>
<kwd lng="en"><![CDATA[cost-benefit]]></kwd>
<kwd lng="en"><![CDATA[evaluation]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oscanoa]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Access and usability to medications: a proposal for an operational definition]]></article-title>
<source><![CDATA[Rev Peru Med Exp Salud Publica]]></source>
<year>2012</year>
<volume>29</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>119-26</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Román Collazo]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Urgilez Pesantez]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Andrade Campoverde]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ethical considerations in the dispensing of medications in pharmacies in Ecuador]]></article-title>
<source><![CDATA[Rev Habanera Ciencias Medicas]]></source>
<year>2020</year>
<volume>19</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>76-92</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<collab>DIGEMID</collab>
<source><![CDATA[Analizan situación de medicamentos en el Perú]]></source>
<year>2019</year>
<publisher-name><![CDATA[DIGEMID]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dongo]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Law N° 29459 of pharmaceutical products, medical devices and sanitary products]]></article-title>
<source><![CDATA[Rev Peru Med Exp Salud Publica]]></source>
<year>2009</year>
<volume>26</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>529</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ciquero Cruzado]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<source><![CDATA[Farmacoeconomia y terapia con carbapenémicos en pacientes hospitalizados en Hospital Nacional Dos de Mayo 2017. Repositorio Institucional - UCV]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Lima ]]></publisher-loc>
<publisher-name><![CDATA[Universidad César Vallejo]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández-Cortez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acetaminofén: el medicamento más usado en pediatría]]></article-title>
<source><![CDATA[Anest en México]]></source>
<year>2016</year>
<volume>28</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1-4</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sarganas]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Buttery]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Zhuang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Wolf]]></surname>
<given-names><![CDATA[IK]]></given-names>
</name>
<name>
<surname><![CDATA[Grams]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Rosario]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence, trends, patterns and associations of analgesic use in Germany]]></article-title>
<source><![CDATA[BMC Pharmacol Toxicol]]></source>
<year>2015</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-13</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aguilar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ascitelli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Carosella]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Izurieta]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Perandones]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Soverchia]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Prevalencia de automedicación de antiinflamatorios y analgésicos en la práctica ambulatoria]]></source>
<year>2015</year>
<page-range>13-5</page-range><publisher-name><![CDATA[Rev argent Reum.]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saldaña-Flores]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Villalobos-Ticliahuanca]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ballón-Manrique]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[León-Jiménez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frecuencia y características de la automedicación en pacientes con cefalea en atención primaria en Lambayeque, Perú]]></article-title>
<source><![CDATA[Rev Medica Hered]]></source>
<year>2017</year>
<volume>27</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>230</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[Medir precios, disponibilidad, asequibilidad y componentes de los precios de los medicamentos]]></source>
<year>2008</year>
<edition>2nd</edition>
<publisher-loc><![CDATA[Geneva, Zuiza ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization and Health Action International]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sutta Huarca]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<source><![CDATA[Análisis costo-efectividad de los esquemas terapeuticos utilizados en pacientes con hiperplasia obstructiva de prostata en el Hospital Regional PNP Julio Pinto Manrique. Arequipa 2010-2011]]></source>
<year>2013</year>
<publisher-loc><![CDATA[Arequipa ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Católica de Santa María]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aguilera Díaz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-benefits as a Decision Tool for the Investment in Scientific Activities]]></article-title>
<source><![CDATA[Cofin Habana]]></source>
<year>2017</year>
<volume>11</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>322-43</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cabo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cabo]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Bellmont]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Herreros]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Trainini]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medicine based on Efficiency-Based Medicine (Cost-Effectiveness and Cost-Utility) Supporting Evidence-Based Medicine]]></article-title>
<source><![CDATA[Rev Argentina Cardiol]]></source>
<year>2018</year>
<volume>86</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>218-23</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aguilera Díaz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[El costo-beneficio como herramienta de decisión en la inversión en actividades científicas]]></article-title>
<source><![CDATA[Cofin Habana]]></source>
<year>2017</year>
<volume>11</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>322-43</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Loza]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Castillo-Portilla]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rojas]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Huayanay]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Basic principles and methodological considerations of health economic evaluations]]></article-title>
<source><![CDATA[Rev Peru Med Exp Salud Publica]]></source>
<year>2011</year>
<volume>28</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>527</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trapero-Bertran]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acceso a los medicamentos. Evaluación económica]]></article-title>
<source><![CDATA[Ámbito Farm Farm Soc]]></source>
<year>2008</year>
<volume>27</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>15</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paladino]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Paladino]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La evaluación económica de los medicamentos]]></article-title>
<collab>Simposio 2009</collab>
<source><![CDATA[Facultad de Medicina. Universidad de Morón]]></source>
<year>2009</year>
<page-range>1-16</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Larraín Seclén]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Valentín Cajas]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Zelaya Herrera]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
</person-group>
<source><![CDATA[Propuesta de mejora del proceso de abastecimiento de medicamentos a través de compras corporativas, para mejorar el acceso a medicamentos de los asegurados al Seguro Integral de Salud. Repositorio de la Universidad del Pacífico - UP]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Lima ]]></publisher-loc>
<publisher-name><![CDATA[Universidad del Pacífico]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<collab>World Medical Association Declaration of Helsinki</collab>
<article-title xml:lang=""><![CDATA[Ethical Principles for Medical Research Involving Human Subjects]]></article-title>
<source><![CDATA[Clin Rev Educ]]></source>
<year>2013</year>
<volume>310</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>2191-4</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="">
<collab>MINSA - DIGEMID</collab>
<source><![CDATA[Medicamentos esenciales genéricos y sus alternativas de marca]]></source>
<year>2006</year>
<edition>2nd</edition>
<page-range>1-133</page-range><publisher-loc><![CDATA[Lima - Perú ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amat Díaz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Poveda Andrés]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Carrera-Hueso]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Application of pharmacoeconomics in clinical management]]></article-title>
<source><![CDATA[Farm Fundam y Apl]]></source>
<year>2011</year>
<volume>35</volume>
<numero>S2</numero>
<issue>S2</issue>
<page-range>18-24</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Forns]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Precios de los medicamentos: cómo se establecen y cuáles son sus sistemas de control]]></article-title>
<source><![CDATA[Salud Colect]]></source>
<year>2015</year>
<volume>11</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>35-48</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cristancho]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Vecino]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
<name>
<surname><![CDATA[Misas]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost/effectiveness evaluation of three fixed combinations of acetaminophen and opioids in the management of acute pain in Colombia]]></article-title>
<source><![CDATA[Rev Colomb Anestesiol]]></source>
<year>2015</year>
<volume>43</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>87-94</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castro Quiroz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Castro Altamirano]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz Chaparro]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Daniel Cruz M de la]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rivera Silva]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Leiva Silva]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[Estudio de Mercado sobre Medicamentos (EM03-2018)]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Santiago de Chile ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez-Feijoó]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Caro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmaceutical copayment in Spain after the 2012 reform from the user&#8217;s perspective]]></article-title>
<source><![CDATA[Evidence of inequity? Gac Sanit]]></source>
<year>2021</year>
<volume>35</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>138-44</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
